



NON-RENOUNCEABLE RIGHTS ISSUE

On 28 February 2013, OBJ Limited (ASX: OBJ) (**Company**) announced its intention to undertake a capital raising to raise up to approximately \$3.61 million (before expenses of the capital raising).

The Company is now pleased to confirm that it has lodged a prospectus (**Prospectus**) with the Australian Securities and Investments Commission (**ASIC**) for the capital raising which consists of a pro-rata entitlement offer of new shares and free attaching options to the Company's existing eligible shareholders, and also a pro rata entitlement offer of new options to the Company's existing eligible option holders, the details of which are set out further below.

Rights Issue Offer

The Company is pleased to announce a fully underwritten non-renounceable pro rata offer of approximately 235,099,450 fully paid ordinary shares (**New Shares**) to raise approximately \$3,526,492 (before expenses) (**Rights Issue Offer**).

Under the Rights Issue Offer, eligible shareholders (as defined in the Prospectus) will be entitled to subscribe for one (1) New Share for every five (5) fully paid ordinary shares held at the record date, at an issue price of \$0.015 per New Share.

Subscribers of New Shares will also receive two (2) new options to acquire fully paid ordinary shares in the Company (Attaching New Options) for every five (5) New Shares subscribed for and allotted under the Rights Issue Offer at no additional cost. Attaching New Options issued under the Rights Issue Offer will be exercisable at \$0.01 on or before 31 December 2014. The Company will apply to ASX for quotation of the Attaching New Options.

The Rights Issue Offer is fully underwritten by Novus Capital Limited (Novus Capital).

Option Offer

The Company is also pleased to announce a non-renounceable pro rata offer to existing eligible option holders of approximately 86,455,927 new options (**Option Offer Options**) to raise approximately \$86,456 (before expenses) (**Option Offer**).

Under the Option Offer, eligible option holders (as defined in the Prospectus, and does not include related parties of the Company) will be entitled to subscribe for one (1) Option Offer Option for every one (1) existing option held at the record date, at an issue price of \$0.001 per Option Offer Option. The Option Offer Options will be exercisable at \$0.01 on or before 31 December 2014 and will rank equally in all respects with the Attaching New Options issued under the Rights Issue Offer. The Company will apply to ASX for quotation of the Option Offer Options.

The Option Offer is not underwritten.





Cleansing Offer

As part consideration for its services in relation to the Rights Issue Offer, the Company must issue 5,000,000 Options to Novus Capital (or its nominee). To facilitate the secondary sale of the Options to be issued to Novus Capital (or its nominee), the Prospectus is also making an offer of 1,000 'Cleansing Options' at an issue price of \$0.001 per option to raise \$1.00 (Cleansing Offer).

Use of funds

The funds raised by the Rights Issue Offer and Option Offer and the issue of shares upon the exercise of Attaching New Options and Option Offer Options will be applied by the Company to advance its own products program including the Musculoskeletal and Pain Management development (\$2.0 million), Clinical Development Programs (\$0.3 million), Intellectual Property (\$0.3 million) and Technology Expansion Programs (\$0.4 million), with the balance of the funds (after expenses of the offer) being applied to general working capital purposes.

Timetable

The Company has lodged a prospectus with ASIC today which sets out the material information relating to the Rights Issue Offer, Option Offer and Cleansing Offer.

A copy of the Prospectus and an Appendix 3B in respect of the capital raising accompanies this announcement. The Prospectus, together with an application form, will also be mailed to all eligible shareholders and eligible optionholders as per the timetable below. The Prospectus will also be available on the Company's website www.obj.com.au.

The Company expects the capital raising to be conducted in accordance with the following timetable:





New securities quote on an "ex" basis (the "Ex" date)	20 March 2013
Record date for the Rights Issue Offer and Option Offer	26 March 2013
Prospectus with application form despatched	3 April 2013
Rights Issue Offer, Option Offer and Cleansing Offer opens	3 April 2013
Rights Issue Offer and Option Offer closes	17 April 2013 at
	5.00pm (WST)
New securities quoted on a deferred settlement basis	18 April 2013
Allotment and issue of new securities	26 April 2013
Despatch of holding statements for new securities	26 April 2013
Normal trading of new securities commences on the ASX	29 April 2013
Cleansing Offer Closes	29 April 2013

This timetable is indicative only and subject to change. The Company reserves the right to vary the above dates, subject to the ASX Listing Rules and Corporations Act.

- Ends -

For more information:

Mr Glyn Denison Director P +618 9443 3011

E info@obj.com.auW www.obj.com.au





OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors.

OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

About OBJ's Technologies

OBJ has developed a platform of physical enhancement technologies based on low-cost magnetic micro-arrays that influence the movement and penetration of drugs, active ingredients and formulations at the molecular level.

Complex 3-D array and moving magnetic fields have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of certain biological and non-biological targets.

OBJ develops low cost micro-array film technology that utilises diamagnetic repulsion, induced permeation and energy redirection to offer a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical and consumer products.

Forward-looking Statements

This announcement contains certain "forward-looking statements" concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.